Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.66 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.66 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.50 |
| ▸ | HTR3B | O95264 | 1/20 | 0.50 |
| ▸ | HTR3A | P46098 | 1/20 | 0.50 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.50 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.50 |
| ▸ | OPRD1 | P41143 | 8/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.43 |
| ▸ | HTR1A | P08908 | 2/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.43 |
| ▸ | DRD1 | P21728 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7440184 | 0.82 | CYP19A1 (0.76) | CYP2D6CYP19A1HTR3EHTR3BHTR3A | |
| SCHEMBL31023958 | 0.82 | CYP2D6 (0.51) | CYP2D6CYP19A1OPRD1OPRM1MEN1 | |
| SCHEMBL1137956 | 0.81 | CYP2D6 (1.00) | CYP2D6CYP19A1HTR3EHTR3BHTR3A | |
| Norchlorcyclizine SCHEMBL588655 | 0.75 | CYP2D6 (0.86) | CYP2D6CYP19A1OPRD1OPRM1MEN1 | |
| Norchlorcyclizine SCHEMBL467086 | 0.75 | CYP2D6 (0.86) | CYP2D6CYP19A1OPRD1OPRM1MEN1 | |
| Norchlorcyclizine SCHEMBL6556514 | 0.75 | CYP2D6 (0.86) | CYP2D6CYP19A1OPRD1OPRM1MEN1 | |
| Norchlorcyclizine SCHEMBL588155 | 0.74 | CYP2D6 (0.83) | CYP2D6CYP19A1OPRD1OPRM1MEN1 | |
| SCHEMBL16757291 | 0.74 | CYP2D6 (0.83) | CYP2D6CYP19A1HTR3EHTR3BHTR3A | |
| Norchlorcyclizine SCHEMBL4649874 | 0.74 | CYP2D6 (0.83) | CYP2D6CYP19A1OPRD1OPRM1MEN1 | |
| SCHEMBL10901072 | 0.74 | OPRD1 (0.79) | CYP2D6CYP19A1OPRD1OPRM1CHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160250187-A1 | PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | ASTEX THERAPEUTICS LTD (GB) | 2016-09-01 | — | — | US | disclosed |
| US-20160250187-A1 | PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | ASTEX THERAPEUTICS LTD (GB) | 2016-09-01 | — | — | US | disclosed |
| US-9283226-B2 | Pyrazole derivatives as protein kinase modulators | ASTEX THERAPEUTICS LIMITED (GB) | 2016-03-15 | — | — | US | disclosed |
| US-20140271662-A1 | PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | ASTEX THERAPEUTICS LTD (GB) | 2014-09-18 | — | — | US | disclosed |
| US-20140271662-A1 | PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | ASTEX THERAPEUTICS LTD (GB) | 2014-09-18 | — | — | US | disclosed |
| US-8691806-B2 | Pyrazole derivatives as protein kinase modulators | ASTEX THERAPEUTICS LIMITED (GB) | 2014-04-08 | — | — | US | disclosed |
| US-8541461-B2 | Pharmaceutical combinations comprising pyrazole derivatives as protein kinase modulators | ASTEX THERAPEUTICS LIMITED (GB) | 2013-09-24 | — | — | US | disclosed |
| US-8541461-B2 | Pharmaceutical combinations comprising pyrazole derivatives as protein kinase modulators | ASTEX THERAPEUTICS LIMITED (GB) | 2013-09-24 | — | — | US | disclosed |
| US-8541461-B2 | Pharmaceutical combinations comprising pyrazole derivatives as protein kinase modulators | ASTEX THERAPEUTICS LIMITED (GB) | 2013-09-24 | — | — | US | disclosed |
| US-20130005702-A1 | PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2013-01-03 | — | — | US | disclosed |
| US-20110144080-A1 | PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2011-06-16 | — | — | US | disclosed |
| EP-1706385-B1 | PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | ASTEX THERAPEUTICS LTD (GB) | 2010-10-06 | — | — | EP | disclosed |
| EP-2228369-A1 | Pyrazole derivatives as protein kinase modulators | Astex Therapeutics Ltd. (GB) | 2010-09-15 | — | — | EP | disclosed |
| EP-2228369-A1 | Pyrazole derivatives as protein kinase modulators | Astex Therapeutics Ltd. (GB) | 2010-09-15 | — | — | EP | disclosed |
| US-20100166699-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2010-07-01 | — | — | US | disclosed |
| US-20100166699-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2010-07-01 | — | — | US | disclosed |
| US-20100166699-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2010-07-01 | — | — | US | disclosed |
| US-20100130464-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2010-05-27 | — | — | US | disclosed |
| US-20100130464-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2010-05-27 | — | — | US | disclosed |
| US-20100130464-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144080-A1 | PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | GRK3, GRK2, NR0B2 | CYP2D6 2700/4885CYP19A1 887/4885HTR3E 716/4885 |
| US-20130005702-A1 | PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | PRKCB, MAP3K19, MAP4K2 | CYP2D6 2204/4885CYP19A1 1850/4885HTR3E 3520/4885 |
| US-20140271662-A1 | PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | GRK3, GRK2, NR0B2 | CYP2D6 2720/4885CYP19A1 781/4885HTR3E 812/4885 |
| US-20100130464-A1 | PHARMACEUTICAL COMPOUNDS | GRK3, GRK4, GRK2 | CYP2D6 1071/4885CYP19A1 376/4885HTR3E 348/4885 |
| US-20100166699-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | GRK3, ERBB3, NCOA3 | CYP2D6 2107/4885CYP19A1 1449/4885HTR3E 381/4885 |
| US-20160250187-A1 | PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | GRK3, GRK2, NR0B2 | CYP2D6 2720/4885CYP19A1 781/4885HTR3E 812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.